Tri Murti Andayani

Dr. Tri Murti Andayani


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2024 in Malaysian Journal of Medical Sciences
Verified
Journal Article
Open access
EUEka Kartika Untari
Eka Kartika Untari
TATri Murti Andayani
Tri Murti Andayani
NYNanang Munif Yasin
Nanang Munif Yasin
RARizka Humardewayanti Asdie
Rizka Humardewayanti Asdie
Since diabetic foot ulcers (DFUs) are common among diabetes patients, it is essential to increase patients’ knowledge and self-care practices to ensure early recognition and management and reduce amputation risk. Therefore, the goal of this review was to identify the range and level of knowledge of people with DFUs and the type of self-care they undertake. A literature review was conducted using the electronic databases PubMed and Google scholar with ‘diabetic foot’, ‘selfcare’, ‘practice’ and ‘behaviour’ as searching keywords. The identification and selection process were conducted to sort the eligible papers through the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The criteria are the original papers describing knowledge and practice in DFU; reporting knowledge and practice in their non-intervention studies; writing in English language; and publishing between years 2016 and 2022. The eligible papers were assessed using the strength of reporting observational studies in epidemiology (STROBE) checklist for appraising their quality. Twenty-two papers of 2,073 titles met the inclusion criteria and included in the review. The lowest and the highest quality score of included papers based on STROBE checklist are 11 and 26, respectively. The included papers showed various levels of knowledge from good to poor, which prominent the highest percentage are 88% (good knowledge) and 84.8% (poor knowledge). The majority of the foot-care activities found in the reviewed papers involved the following steps: washing, drying, applying moisturiser and trimming nails routinely. Those activity should be followed by checking the feet with a mirror for ulcers, looking for ingrown nails, choosing appropriate footwear, not walking barefoot and routinely consulting a healthcare provider. The knowledge levels were found variable and acceptable. Daily foot care, choosing the right footwear, foot activity and regular health checks should all be used to manage diabetes.

5 April 2023 in Pharmacy Practice
Verified
Journal Article
Open access
PDF file
FYFitriana Yuliastuti
Fitriana Yuliastuti
TATri Murti Andayani
Tri Murti Andayani
DEDwi Endarti
Dwi Endarti
SKSusi Ari Kristina
Susi Ari Kristina
Background: In Indonesia, the cost of cancer treatment has been determined by the Indonesian Case Base Groups (INA-CBGs) based on a code called the INA-CBG’s rates. However, a fair claim should be based on the severity of the disease and the class of treatment in the hospital, not on the rates of code. In fact, the real cost of therapy for cancer is influenced by several factors including stage, comorbidity, and severity (INA-CBGs coding, type of hospital, hospital class, treatment grade, side effects, and length of stay), so in many cases, there are reported differences between the real costs and the INA-CBGs rates charged to patients. Objective: This study aims to investigate the difference between real treatment costs and INA-CBG’s rates for cases of lung cancer, cervical cancer, and breast cancer at a cancer center hospital in Indonesia. Methods: This work uses an observational study, and the data were taken retrospectively from hospital financial data and patient medical records. The data were then analyzed using a one-sample t-test to determine the difference between real costs and INA-CBGs costs. Results: The results showed that there was no significant difference between real costs and INA-CBG’s cost on stage II lung cancer treatment in grade 2 with a sig. value of 0.683; code C-4-13-II in grade 3 with a sig. value of 0.151; and code C-4-13-III in grade 3 with a sig. value of 0.650; where the significance level (t alpha) is more than 0.05. Furthermore, the treatment costs for cervical cancer with codes C-4- 13-I and C-4-13-II in grade 1 had sig. values of 0.155 and 0.720 respectively. Lastly, the treatment cost for breast cancer patients with codes C-4-12-II in grade 3 had a sig. value of 0.145 and code C-4-13-II in grade 3 showed a sig. value of 0.091. Conclusion: Although statistical evaluation showed a significant difference for some cases and not significant for other cases, in real conditions, there is a difference between the INA-CBGs and the real costs that must be evaluated by the government and stakeholders to provide justice for cancer patients. Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology

1 May 2020 in Value in Health Regional Issues
Verified
Journal Article
Closed access
TATri Murti Andayani
Tri Murti Andayani
SKSusi A. Kristina
Susi A. Kristina
DEDwi Endarti
Dwi Endarti
RHRestu N.H. Haris
Restu N.H. Haris
ARAnindya Rahmawati
Anindya Rahmawati

1 January 2025 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Closed access
DEDwi Endarti
Dwi Endarti
TATri Murti Andayani
Tri Murti Andayani
AWAnna Wahyuni Widayanti
Anna Wahyuni Widayanti
SRSyifaur Rohmah
Syifaur Rohmah
RBResi Rizki Banjarani
Resi Rizki Banjarani
NGNurul Adzkia Ghearizky
Nurul Adzkia Ghearizky
Context: Chronic disease treatment can lead to catastrophic costs. Although most direct medical costs are covered by the National Health Insurance, direct nonmedical and indirect costs may be burdensome for patients. Aims: To estimate the cost of chronic diseases from a patient’s perspective. Methods: A total of 315 patients with stroke (n = 105), heart disease (n = 108), and chronic kidney disease (n = 102) visiting a district hospital in Yogyakarta Province in Indonesia were included in this study. Data were collected through interviews and analyzed using descriptive statistics. Significant differences in mean costs between different groups seeking healthcare facilities were determined using the Mann–Whitney U test. Results: The estimated total out-of-pocket (OOP) costs per patient within three months were IDR 3,411,662 (USD 227.4), IDR 632,665 (USD 42.2), and IDR 3,227,951 (USD 215.2) for stroke, heart disease, and chronic kidney disease, respectively. OOP costs for the three diseases accounted for 9–49% of minimum regional wages. Indirect costs were the highest costs contributing to the total OOP cost (33–64%), followed by direct medical costs (12–57%) and direct nonmedical costs (5–33%). Patients seeking additional treatment at other healthcare facilities tended to have significantly higher costs. Conclusions: This study showed that chronic diseases put a relatively high economic burden on patients. Additionally, seeking more healthcare facilities tends to increase costs.

1 July 2023 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
ESEndang Sunariyanti
Endang Sunariyanti
TATri Murti Andayani
Tri Murti Andayani
DEDwi Endarti
Dwi Endarti
DPDiah Ayu Puspandari
Diah Ayu Puspandari
Objective: The cost of treating chronic kidney disease requires large funds. Chronic kidney disease financing ranks 2nd in BPJS as the highest financing. All cost components in the treatment of chronic kidney disease are considered high, so adjustments and efficiency are needed. This study aims to perform a cost analysis in chronic kidney patients. In this article, we will discuss the cost components in treatment and see whether there are differences in the cost of treatment in each hospital. Methods: The study used a cross-sectional design with a hospital perspective and was conducted in 6 hospitals selected based on class in different regions: Sardjito Central General Hospital (class A), Yogyakarta Regional General Hospital (class B) and PKU Muhammadiyah Hospital (private class) represent hospitals in regional 1. Meanwhile, Makassar Central General Hospital (class A), Labuang Hospital Baji (class B) and Faisal Islamic Hospital (private class) represent hospitals in regional 3. The study lasted for 14 months from October 2019-December 2020. The total sample involved in this study was 582 samples. The cost components analyzed include hemodialysis costs, serious procedures and operations, services, radiology, laboratories, blood transfusions, drugs, medical devices, hospitalization and supplies. Results: Chronic kidney patient profile data, calculations and cost components are presented descriptively. The Mann–Whitney test was used to see whether there were differences in costs between hospitals in each region. The results showed that the total cost of treating chronic kidney disease was higher in class A hospitals compared to class B and private class hospitals. Conclusion: The highest cost component is the cost of hemodialysis, followed by severe procedures and services. The highest total cost of hemodialysis reached Rp. Rp.840,132,546, heavy action Rp. 423,156,000 and services Rp. 792,155,000. The results of statistical tests showed that there were differences in the cost of treating chronic kidney disease in hospitals in regional 1 and regional 3 (p < 0.05).

1 December 2016 in Indonesian Journal of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
SHSri Haryanti
Sri Haryanti
ISIndonesia Stifar Yaphar Semarang
Indonesia Stifar Yaphar Semarang
ZIZullies Ikawati
Zullies Ikawati
TATri Murti Andayani
Tri Murti Andayani
MMMustofa Mustofa
Mustofa Mustofa
FTFakultas Kedokteran Departemen Farmakologi Dan Terapi
Fakultas Kedokteran Departemen Farmakologi Dan Terapi
Asma tetap menjadi masalah kesehatan yang dialami banyak anak-anak dan orang dewasa di dunia. Sebagai penyakit kronis, tata laksana asma memerlukan pengobatan yang berkelanjutan. Salah satu masalah penting dalam tata laksana asma adalah kepatuhan dalam pengobatan. Kepatuhan yang rendah terhadap anti-asma yang diberikan menyebabkan meningkatnya morbiditas dan mortalitas. Penelitian ini dilakukan untuk mengkaji hubungan kepatuhan terhadap anti-asma yang diberikan dengan kontrol asma. Penelitian ini merupakan penelitian observasional menggunakan rancangan potong lintang yang dilakukan di empat rumah sakit di Daerah Istimewa Yogyakarta selama enam bulan, yaitu antara bulan Juni sampai Desember 2015. Subjek penelitian adalah pasien dengan gangguan fungsi pernafasan yang menjalani pengobatan di poliklinik penyakit dalam di rumah sakit tersebut dan memenuhi kriteria inklusi dan eksklusi serta bersedia ikut dalam penelitian dengan menandatangani surat pernyataan persetujuan. Kepatuhan diukur dengan Morisky Medication Adherence Scale (MMAS) dan kontrol asma diukur dengan Asthma Control Test (ACT). Uji korelasi Pearson digunakan untuk mengkaji hubungan antara kepatuhan dan kontrol asma. Total sebanyak 67 pasien diseleksi dan 57 diantara memenuhi kriteria inklusi dan eksklusi. Berdasarkan kepatuhannya, pasien dikelompokkan ke dalam kepatuhan sedang (31 pasien atau 54%) dan kepatuhan rendah (26 pasien atau 46%). Berdasarkan kontrol asma, pasien dikelompokkan ke dalam kontrol asma sebagian (11 pasien atau 19%) dan tidak terkontrol asma (47 pasien atau 81%). Terdapat hubungan signifikan antara kepatuhan dengan kontrol asma (r=0,303, p<0,05). Kesimpulan, kepatuhan terapi dapat meningkatkan kontrol asma. Kata kunci: Anti-asma, kepatuhan, kontrol asma, tata kelola asma Relationship Between Compliance of Using β2-Agonist Inhaler Drugand Asthma Control on Asthma Patient Asthma remains a health problem affecting a large number of children and adult in the world. Being a chronic disease, asthma management requires continous medications. One of the most important issues in asthma management is adherence to treatment. Poor compliance with prescribed anti-asthma leads to increase in morbidity and mortality. This study was conducted to evaluate the relationship between ompliance prescribed anti-asthma and asthma control. This was an observasional study using cross-sectional design conducted in four hospitals around Province of DI Yogyakarta during six months om June until December 2015. Subjects were patients with respiratory disorders who underwent treatment in internal medicine polyclinic in the hospitals, met the inclusion and exclusion criteria and willing to participate in the study by signing the informed consent. Compliance was assesseed by Morisky Medication Adherence Scale (MMAS) and asthma control was assessed by Asthma Control Test (ACT). Pearson’s correlation test was used to evaluate the relationship between compliance and asthma control. A total of 67 patients were selected and 57 of them met the inclusion and exclusion criteria. Based on the patient’s compliance, the patients were grouped into moderate compliance (31 patients or 54%) and low compliance (26 patients or 46%). Whereas based on the asthma control, the patients were grouped into partly controlled asthma (11 patient or 19%) and uncontrolled asthma (47 patients or 81%). There is a significant relationship between compliance with asthma control (r=0303, p<0.05). Conclusion, compliance can increase asthma control. Keywords: Anti-asthma, asthma control, asthma management, compliance